Cosentyx Drug Global Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

Cosentyx (secukinumab) is a prescription biologic therapy developed by Novartis. It is a monoclonal antibody that works by inhibiting interleukin-17A (IL-17A), a protein that plays a key role in inflammatory processes. Cosentyx is mainly prescribed for the treatment of autoimmune disorders such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. It is administered through subcutaneous injection and helps alleviate inflammation, improve skin symptoms, and reduce joint damage. The medication has demonstrated effectiveness in enhancing the quality of life of patients living with these chronic conditions.

The primary indication types of Cosentyx include hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. Hidradenitis suppurativa is a long-term skin disorder characterized by painful nodules, abscesses, and scarring, commonly affecting areas with sweat glands such as the underarms and groin. The routes of administration include subcutaneous injection and intravenous infusion, while the distribution channels consist of hospital pharmacies, online pharmacies, and retail pharmacies.

Tariffs have influenced the cosentyx drug market by increasing costs for biologic manufacturing inputs, injection devices, and cold-chain distribution infrastructure. These pressures are more visible in hospital pharmacy and specialty retail channels. North america and europe face reimbursement challenges due to biologic pricing sensitivity. However, tariffs are encouraging localized biologics production and packaging operations. This is improving supply stability and reducing dependency on international manufacturing.

The cosentyx drug market research report is one of a series of new reports from The Business Research Company that provides cosentyx drug market statistics, including cosentyx drug industry global market size, regional shares, competitors with a cosentyx drug market share, detailed cosentyx drug market segments, market trends and opportunities, and any further data you may need to thrive in the cosentyx drug industry. This cosentyx drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cosentyx drug market size has grown strongly in recent years. It will grow from $5.68 million in 2025 to $6.21 million in 2026 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to approval of il 17 inhibitors, high prevalence of psoriasis and arthritis, limited response to tnf inhibitors, specialist dermatology adoption, biologic treatment guidelines.

The cosentyx drug market size is expected to see strong growth in the next few years. It will grow to $8.74 million in 2030 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to growth in autoimmune disease diagnosis, expansion of treatment indications, increasing patient awareness, improved biologic accessibility, long term efficacy data support. Major trends in the forecast period include growing adoption of il 17 inhibitor therapies, expansion of use across autoimmune indications, shift toward targeted biologic treatments, increased use of long term maintenance therapy, rising demand for self injectable biologics.

The increasing prevalence of autoimmune diseases is anticipated to drive the growth of the Cosentyx market in the coming years. Autoimmune diseases are conditions in which the immune system mistakenly attacks the body's own healthy cells and tissues. The rising incidence of these diseases is linked to factors such as genetic susceptibility, environmental influences including infections and pollutants, and lifestyle changes such as higher stress levels and dietary modifications. Cosentyx (secukinumab) supports patients with autoimmune diseases by selectively targeting and inhibiting interleukin-17A, a key cytokine involved in inflammatory processes, thereby reducing disease symptoms, improving quality of life, and effectively managing conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. For instance, in August 2024, according to data from Public Health Scotland, a Scotland-based national organization, the Scottish Multiple Sclerosis Register recorded 455 newly diagnosed multiple sclerosis patients in 2023. Therefore, the rising prevalence of autoimmune diseases is driving the growth of the Cosentyx market.

Rising healthcare expenditure is expected to further propel the growth of the Cosentyx market going forward. Healthcare expenditure refers to the overall spending on healthcare goods and services, including personal medical care, preventive services, and public health initiatives, aimed at improving health outcomes over a specific period. The increase in healthcare spending is driven by factors such as an aging population, the growing burden of chronic diseases, advancements in medical technology, high drug costs, inefficient payment systems, and rising demand for healthcare services. Spending related to Cosentyx is mainly focused on the management of moderate to severe psoriasis, psoriatic arthritis, and ankylosing spondylitis, with the goal of improving patient outcomes through targeted biologic therapy. For instance, in May 2024, according to a report published by the Office for National Statistics, a UK-based government agency, total healthcare expenditure increased by 5.6% in nominal terms from 2022 to 2023, compared to a growth rate of 0.9% in 2022. As a result, rising healthcare expenditure is contributing to the expansion of the Cosentyx market.

Leading companies operating in the Cosentyx drug market are concentrating on the development of advanced therapies, including biologic treatment options, to address unmet medical needs, enhance treatment effectiveness, and deliver targeted solutions for the management of chronic autoimmune conditions, thereby strengthening their market presence and serving a growing patient population. Biologic therapies are sophisticated treatments derived from living organisms or their components that specifically target elements of the immune system, such as interleukin-17A, to regulate inflammatory responses and effectively treat autoimmune disorders including psoriasis, psoriatic arthritis, and ankylosing spondylitis. For instance, in October 2023, Novartis AG, a Switzerland-based pharmaceutical company, received FDA approval for Cosentyx (secukinumab) as the first new biologic treatment for moderate to severe hidradenitis suppurativa in nearly ten years. This approval represents a major advancement in the treatment landscape for hidradenitis suppurativa, a chronic and often debilitating skin condition marked by painful lesions that can result in scarring and significant psychological distress.

Major companies operating in the cosentyx drug market are Novartis AG

North America was the largest region in the cosentyx drug market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cosentyx drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the cosentyx drug market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

The cosentyx drug market consists of sales oflyophilized powder, and self-administered autoinjector. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cosentyx Drug Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses cosentyx drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cosentyx drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cosentyx drug market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Indication: Hidradenitis suppurativa; Psoriatic arthritis; Ankylosing spondylitis; Plaque Psoriasis
• 2) By Route Of Administration: Subcutaneous injection; Intravenous infusion
• 3) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies
• Companies Mentioned: Novartis AG
• Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.